Long Covid or Epstein Barr? (and What Helps)

Written by Erin Porter

The EBV-long COVID link is real and increasingly well-supported — particularly the Gold et al. (2021) study finding ~67% EBV reactivation in long COVID patients. More recent reviews have continued to build on this.

Wow, that’s almost 70% (that they know of.) This is exactly what happened to me, Epstein Barr was reactivated and I was on a mission to force it gently back into dormancy! Timelines Mitopure was one of the major players I used, and in the next post, I will list everything I used in my arsenal to do just that. This is not just for long haul Covid or Esptein Barr, it’s for anyone with any type of chronic illness.

The Invisible Epidemic Inside Your Cells

Millions of people recovering from COVID-19 are caught in a frustrating paradox: the infection is gone, but the symptoms aren’t. Crushing fatigue. Brain fog that won’t lift. Muscle weakness that makes a short walk feel like a marathon. For many, answers have been elusive — until researchers started looking not just at the virus itself, but at what happens to our cells in its wake.

At the center of this emerging story are mitochondria — the energy-producing engines of every cell in your body. And increasingly, a naturally derived compound called Mitopure (urolithin A) is being studied for its ability to restore mitochondrial function, reduce inflammation, and even support immune resilience. Here’s what the science shows — and why it matters for people struggling with long COVID, reactivated Epstein-Barr virus (EBV), and related post-viral conditions.

What Is Mitopure?

Mitopure is a highly purified, clinically tested form of urolithin A (UA) — a postbiotic compound produced when gut bacteria metabolize polyphenols found in pomegranates, berries, and walnuts. The challenge is that most people’s gut microbiomes don’t produce sufficient urolithin A from diet alone, which is where supplementation comes in.

Urolithin A’s primary mechanism is the induction of mitophagy — the cellular process of identifying, clearing, and recycling damaged mitochondria. Think of it as a quality control system for your cells’ power plants: old, dysfunctional mitochondria get cleared out, and the cell can build newer, more efficient ones in their place. Right now they are offering 20% off Mitopure.

The Long COVID-Mitochondria Connection

Long COVID — defined broadly as persistent symptoms lasting beyond 12 weeks after acute SARS-CoV-2 infection — affects an estimated 10–30% of those infected. Its hallmarks include debilitating fatigue, cognitive impairment (“brain fog”), exercise intolerance, myalgias, and sleep disruption.

These symptoms have a striking parallel with mitochondrial dysfunction. Research has proposed that SARS-CoV-2 directly impairs mitochondrial function through several mechanisms, including disruption of mitochondrial membrane integrity, induction of oxidative stress, and interference with energy metabolism pathways. Those with already-compromised mitochondria — the elderly, those with metabolic comorbidities — appear most vulnerable to severe and prolonged disease.

The Epstein-Barr Virus Connection: A “Double Whammy”

Here’s where the story gets more complex — and more important. Epstein-Barr virus (EBV) is a herpesvirus that infects more than 90% of the global population and typically enters a state of latency after primary infection. Under conditions of immune stress, it can reactivate.

COVID-19 appears to be a potent trigger for this reactivation. One landmark study found that 66.7% of long COVID patients tested positive for EBV reactivation, compared to just 10% of COVID-recovered patients without long COVID symptoms. The symptoms reported by those with concurrent EBV reactivation and long COVID included fatigue (58.6%), insomnia (48.3%), headaches and myalgia (44.8% each), brain fog (41.4%), weakness, rash, and others.

Subsequent research has continued to strengthen this association. A 2023 study confirmed that COVID-19 patients showed increased incidence of EBV reactivation compared to non-COVID patients, and recent reviews have concluded that EBV reactivation has significantly contributed to the exacerbation and prolongation of long COVID symptoms in a substantial subset of patients.

Why does COVID reactivate EBV? The immune dysregulation caused by SARS-CoV-2 — including T cell exhaustion, NK cell dysfunction, and chronic inflammation — appears to remove the immune brakes that normally keep latent EBV in check. SARS-CoV-2 persistent infection, activation of latent viruses, immune dysregulation, and organ dysfunction have all been proposed as mechanisms.

And critically, EBV itself is well known to modulate mitochondrial function. Researchers have described this as a potential mitochondrial “double whammy”: COVID impairs mitochondria, and then reactivated EBV compounds that damage further, creating a cycle of cellular energy failure and immune dysregulation that perpetuates long COVID symptoms.

ME/CFS: The Third Piece of the Puzzle

Long COVID shares significant clinical and immunological overlap with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) — a condition that has long been associated with post-viral triggers, including prior EBV infection. Both conditions present with profound fatigue, exercise intolerance, sleep disorders, cognitive dysfunction, and neurological complaints. Both also show EBV reactivation, immune dysregulation, and markers of mitochondrial impairment, suggesting a common underlying pathway. For patients with long COVID who meet criteria for ME/CFS, understanding this viral-mitochondrial axis is especially relevant.

Where Mitopure Fits In: The Biological Rationale

While no clinical trials have yet directly studied Mitopure in long COVID or EBV reactivation, the mechanistic case for its potential benefit is substantial — built on converging lines of published evidence.

1. Restoring Mitochondrial Quality Control

Multiple randomized, placebo-controlled trials have demonstrated that urolithin A supplementation induces a measurable molecular signature of improved mitochondrial health in humans. In one 4-month trial in middle-aged adults, Mitopure produced significant improvements in muscle strength (~12%), aerobic endurance, and physical performance, alongside meaningful reductions in plasma acylcarnitines and C-reactive protein — biomarkers of mitochondrial efficiency and systemic inflammation. If mitochondrial dysfunction is a core driver of post-viral fatigue, this mechanism is directly relevant.

2. Reducing Systemic Inflammation

Chronic inflammation is central to both long COVID and EBV reactivation pathology. Urolithin A has demonstrated anti-inflammatory effects across multiple tissues — including brain, adipose, heart, and liver — through inhibition of NF-κB signaling, reduction of reactive oxygen species (ROS), and suppression of pro-inflammatory cytokines. In clinical trials, Mitopure supplementation reduced plasma levels of CRP and several other inflammatory markers.

3. Supporting Immune Function

Perhaps most intriguing is Mitopure’s emerging data on immune modulation. In a recent randomized, placebo-controlled trial (the MitoImmune study), UA supplementation in healthy middle-aged adults increased peripheral NK cells and nonclassical monocytes, augmented mitochondrial biogenesis in CD8+ T cells, and improved T cell activation and bacterial uptake by monocytes. Single-cell RNA sequencing revealed UA-driven transcriptional shifts across multiple immune cell populations, modulating pathways linked to inflammation and metabolism. Since EBV reactivation is fundamentally a failure of immune surveillance — particularly NK cell and CD8+ T cell control of latently infected B cells — improving the functional fitness of these cell populations is a mechanistically rational target.

4. Fighting Fatigue at the Cellular Level

Fatigue in long COVID and reactivated EBV is not just psychological — it has a cellular substrate. Urolithin A has been shown to enhance mitochondrial ATP production, improve muscle energy metabolism, delay the onset of muscle fatigue, and reduce oxidative stress-induced mitochondrial damage. In older adults, Mitopure significantly improved muscle endurance (measured as contractions to fatigue) and reduced ceramide and acylcarnitine levels, biomarkers directly linked to mitochondrial inefficiency.

5. Neurological and Cognitive Support

Brain fog is among the most disabling features of long COVID. Urolithin A’s health benefits have been described across multiple tissues including the brain, and its anti-inflammatory properties include documented effects on neuroinflammation. Improving neuronal mitochondrial health and reducing central nervous system inflammation represent plausible pathways for addressing cognitive symptoms, though direct human data in this context is still emerging.

Beyond Long COVID: Other Conditions Where Mitopure Shows Promise

The mitochondrial and inflammatory pathways targeted by urolithin A are relevant across a broad range of chronic conditions:

Sarcopenia and age-related muscle decline: Multiple RCTs support meaningful improvements in muscle strength and endurance.
Osteoarthritis: Urolithin A improved mitophagy and mitochondrial respiration in human chondrocytes and reduced cartilage degeneration and pain in preclinical OA models.
Neurodegenerative disease: Preclinical data suggests benefit in Alzheimer’s models, consistent with the role of mitophagy in neuronal health.
Inflammatory bowel disease: Anti-inflammatory effects in the gut have been documented.
Heart failure: Preclinical evidence suggests benefits for cardiac mitochondrial function.
- Type 2 diabetes and metabolic disease: UA’s immunomodulatory properties extend to adipose tissue and liver, potentially relevant to insulin resistance and NAFLD.
Important Caveats
The evidence linking Mitopure to long COVID and EBV reactivation is mechanistic and inferential at this stage — not based on direct clinical trials in these populations. The connection is scientifically plausible and supported by converging lines of evidence, but it would be premature to describe urolithin A as a proven treatment for these conditions.
Notably, not everyone’s gut microbiome produces urolithin A efficiently from dietary sources — which is part of the rationale for supplementing with a purified, bioavailable form like Mitopure. Doses used in clinical trials have generally ranged from 500–1,000 mg daily, and the compound has demonstrated a strong safety profile across trials.For patients with long COVID, reactivated EBV, or ME/CFS, Mitopure represents a compelling area of emerging research — one worth discussing with a knowledgeable clinician, particularly in the context of a broader, individualized recovery strategy.
The Bottom Line
The intersection of long COVID, EBV reactivation, and mitochondrial dysfunction represents one of the most important frontiers in post-viral medicine. The evidence that SARS-CoV-2 triggers EBV reactivation in a significant proportion of long COVID patients — and that both viruses converge on mitochondrial impairment — points toward cellular energy restoration as a potentially crucial therapeutic target.
Mitopure, as the best-characterized clinical-grade mitophagy activator available, sits squarely at this intersection: restoring mitochondrial quality, reducing systemic inflammation, and — based on emerging data — supporting the immune surveillance machinery that keeps latent viruses like EBV in check.
The clinical trials are still catching up. But the biology is compelling.

Check out the second edition of my book Eat Pray Get Well on Amazon KINDLE for just $9.99

References: Gold et al., Pathogens (2021); Bernal & Whitehurst, Virus Research (2023); Singh et al., Cell Metabolism (2022); Liu et al., JAMA Network Open (2022); Denk et al., Nature Aging (2025); Andreux et al., Nature Metabolism (2019); D’Amico et al., PMC (2021); Harber et al., PMC (2022) — Long COVID and mitochondrial health.